{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:49:19Z","timestamp":1771649359115,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T00:00:00Z","timestamp":1724112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Johnson and Johnson Innovative Medicine, LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s12325-024-02963-1","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T09:02:44Z","timestamp":1724144564000},"page":"3922-3933","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Long-Term Persistence and Surgical Procedure-Free Period Among Bio-na\u00efve Patients with Crohn\u2019s Disease and Fistula Initiated on Ustekinumab"],"prefix":"10.1007","volume":"41","author":[{"given":"Maryia","family":"Zhdanava","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumesh","family":"Kachroo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Porpong","family":"Boonmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabree","family":"Burbage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Kerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,20]]},"reference":[{"issue":"1","key":"2963_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmgh.2022.09.011","volume":"15","author":"CGC McGregor","year":"2023","unstructured":"McGregor CGC, Tandon R, Simmons A. Pathogenesis of fistulating Crohn\u2019s disease: a review. Cell Mol Gastroenterol Hepatol. 2023;15(1):1\u201311.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"4","key":"2963_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1053\/gast.2002.32362","volume":"122","author":"DA Schwartz","year":"2002","unstructured":"Schwartz DA, Loftus EV Jr, Tremaine WJ, et al. The natural history of fistulizing Crohn\u2019s disease in Olmsted County. Minnesota Gastroenterol. 2002;122(4):875\u201380.","journal-title":"Minnesota Gastroenterol"},{"issue":"11","key":"2963_CR3","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/ibd\/izz056","volume":"25","author":"D Schwartz","year":"2019","unstructured":"Schwartz D, Tagarro I, D\u00edez M, et al. Prevalence of fistulizing Crohn\u2019s disease in the United States: estimate from a systematic literature review attempt and population-based database analysis. Inflamm Bowel Dis. 2019;25(11):1773\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"2963_CR4","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/2050640613487194","volume":"1","author":"K Gecse","year":"2013","unstructured":"Gecse K, Khanna R, Stoker J, et al. Fistulizing Crohn\u2019s disease: diagnosis and management. United European Gastroenterol J. 2013;1(3):206\u201313.","journal-title":"United European Gastroenterol J"},{"key":"2963_CR5","doi-asserted-by":"publisher","first-page":"goac049","DOI":"10.1093\/gastro\/goac049","volume":"10","author":"KA Dunleavy","year":"2022","unstructured":"Dunleavy KA, Pardi DS. Biologics: how far can they go in Crohn\u2019s disease? Gastroenterol Rep (Oxf). 2022;10:goac049.","journal-title":"Gastroenterol Rep (Oxf)."},{"issue":"11","key":"2963_CR6","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3390\/jcm11113045","volume":"11","author":"P Wetwittayakhlang","year":"2022","unstructured":"Wetwittayakhlang P, Al Khoury A, Hahn GD, et al. The optimal management of Fistulizing Crohn\u2019s disease: evidence beyond randomized clinical trials. J Clin Med. 2022;11(11):3045.","journal-title":"J Clin Med."},{"issue":"9","key":"2963_CR7","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.3390\/ijerph18094872","volume":"18","author":"E Menditto","year":"2021","unstructured":"Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18(9):4872.","journal-title":"Int J Environ Res Public Health."},{"issue":"2","key":"2963_CR8","doi-asserted-by":"publisher","first-page":"otab011","DOI":"10.1093\/crocol\/otab011","volume":"3","author":"J Mahlich","year":"2021","unstructured":"Mahlich J, May M, Feig C, et al. Persistence with biologic therapy and associated costs of patients with inflammatory bowel disease: a German retrospective claims data analysis. Crohns Colitis 360. 2021;3(2):otab011.","journal-title":"Crohns Colitis 360."},{"issue":"9","key":"2963_CR9","doi-asserted-by":"publisher","first-page":"6763","DOI":"10.1074\/jbc.M112.436675","volume":"288","author":"R Jalah","year":"2013","unstructured":"Jalah R, Rosati M, Ganneru B, et al. The p40 subunit of interleukin (IL)-12 promotes stabilization and export of the p35 subunit: implications for improved IL-12 cytokine production. J Biol Chem. 2013;288(9):6763\u201376.","journal-title":"J Biol Chem"},{"key":"2963_CR10","unstructured":"Janssen Pharmaceutical Companies. STELARA (Ustekinumab) [package insert]. U.S. Food and Drug Administration. 2016 [cited 2021 7 July]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761044lbl.pdf"},{"issue":"Supplement_2","key":"2963_CR11","doi-asserted-by":"publisher","first-page":"ii30","DOI":"10.1093\/ecco-jcc\/jjac011","volume":"16","author":"F D'Amico","year":"2022","unstructured":"D\u2019Amico F, Peyrin-Biroulet L, Danese S. Ustekinumab in Crohn\u2019s disease: new data for positioning in treatment algorithm. J Crohns Colitis. 2022;16(Supplement_2):ii30\u201341.","journal-title":"J Crohns Colitis."},{"issue":"7","key":"2963_CR12","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","volume":"160","author":"JD Feuerstein","year":"2021","unstructured":"Feuerstein JD, Ho EY, Shmidt E, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal Fistulizing Crohn\u2019s disease. Gastroenterology. 2021;160(7):2496\u2013508.","journal-title":"Gastroenterology"},{"issue":"16","key":"2963_CR13","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease. N Engl J Med. 2012;367(16):1519\u201328.","journal-title":"N Engl J Med"},{"key":"2963_CR14","doi-asserted-by":"publisher","first-page":"175628482311535","DOI":"10.1177\/17562848231153560","volume":"16","author":"VD Teresa","year":"2023","unstructured":"Teresa VD, Raul OM, Marisa I, et al. Effectiveness and safety of ustekinumab in bio-naive Crohn\u2019s disease patients: a multicentre observational retrospective study. Therap Adv Gastroenterol. 2023;16:17562848231153560.","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"2963_CR15","first-page":"272","volume":"114","author":"L Lorenzo Gonzalez","year":"2022","unstructured":"Lorenzo Gonzalez L, Valdes Delgado T, Vazquez Moron JM, et al. Ustekinumab in Crohn\u2019s disease: real-world outcomes and predictors of response. Rev Esp Enferm Dig. 2022;114(5):272\u20139.","journal-title":"Rev Esp Enferm Dig"},{"issue":"3","key":"2963_CR16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3390\/jcm12030939","volume":"12","author":"J Yao","year":"2023","unstructured":"Yao J, Zhang H, Su T, et al. Ustekinumab promotes radiological fistula healing in perianal fistulizing Crohn\u2019s disease: a retrospective real-world analysis. J Clin Med. 2023;12(3):939.","journal-title":"J Clin Med."},{"key":"2963_CR17","doi-asserted-by":"publisher","first-page":"175628482211443","DOI":"10.1177\/17562848221144349","volume":"15","author":"P Bacsur","year":"2022","unstructured":"Bacsur P, Matuz M, Resal T, et al. Ustekinumab is associated with superior treatment persistence but not with higher remission rates versus vedolizumab in patients with refractory Crohn\u2019s disease: results from a multicentre cohort study. Therap Adv Gastroenterol. 2022;15:17562848221144348.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"2963_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1080\/03007995.2023.2178148","volume":"39","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Ding Z, Manceur AM, et al. Treatment persistence among bio-naive patients with Crohn\u2019s disease initiated on ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(4):533\u201343.","journal-title":"Curr Med Res Opin"},{"issue":"8","key":"2963_CR19","first-page":"907","volume":"29","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Zhao R, Manceur AM, et al. Persistence and other treatment patterns among bio-experienced patients with Crohn\u2019s disease initiated on ustekinumab or adalimumab. J Manag Care Spec Pharm. 2023;29(8):907\u201316.","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"2963_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/apt.16436","volume":"54","author":"Y Ko","year":"2021","unstructured":"Ko Y, Paramsothy S, Yau Y, et al. Superior treatment persistence with ustekinumab in Crohn\u2019s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study. Aliment Pharmacol Ther. 2021;54(3):292\u2013301.","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"2963_CR21","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1007\/s12325-023-02611-0","volume":"40","author":"B Bressler","year":"2023","unstructured":"Bressler B, Jones J, In TSH, et al. Real-world persistence of Ustekinumab in the treatment of inflammatory bowel disease. Adv Ther. 2023;40(10):4421\u201339.","journal-title":"Adv Ther"},{"issue":"1","key":"2963_CR22","first-page":"90","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ferrante SA, Fitzgerald T, et al. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90\u2013100.","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"2963_CR23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1080\/03007995.2023.2246882","volume":"39","author":"M Zhdanava","year":"2023","unstructured":"Zhdanava M, Ding Z, Manceur AM, et al. Long-term persistence and other treatment patterns among bio-naive patients with Crohn\u2019s disease treated with ustekinumab or adalimumab. Curr Med Res Opin. 2023;39(9):1215\u201325.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"2963_CR24","first-page":"495","volume":"44","author":"S Khan","year":"2019","unstructured":"Khan S, Rupniewska E, Neighbors M, et al. Real-world evidence on adherence, persistence, switching and dose escalation with biologics in adult inflammatory bowel disease in the United States: a systematic review. J Clin Pharm Ther. 2019;44(4):495\u2013507.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"2963_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3390\/jcm12020466","volume":"12","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Ouboter LF, Peeters K, et al. Crohn\u2019s Disease-Associated and Cryptoglandular Fistulas: Differences and Similarities. J Clin Med. 2023;12(2):466.","journal-title":"J Clin Med."},{"issue":"1","key":"2963_CR26","doi-asserted-by":"publisher","first-page":"e000702","DOI":"10.1136\/bmjgast-2021-000702","volume":"8","author":"GM Godoy Brewer","year":"2021","unstructured":"Godoy Brewer GM, Salem G, Afzal MA, et al. Ustekinumab is effective for perianal fistulising Crohn\u2019s disease: a real-world experience and systematic review with meta-analysis. BMJ Open Gastroenterol. 2021;8(1):e000702.","journal-title":"BMJ Open Gastroenterol."},{"issue":"25","key":"2963_CR27","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.3748\/wjg.v27.i25.3693","volume":"27","author":"A Vasudevan","year":"2021","unstructured":"Vasudevan A, Bruining DH, Loftus EV Jr, et al. Approach to medical therapy in perianal Crohn\u2019s disease. World J Gastroenterol. 2021;27(25):3693\u2013704.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2963_CR28","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.14309\/ajg.0000000000002152","volume":"118","author":"M Barreiro-de Acosta","year":"2023","unstructured":"Barreiro-de Acosta M, Fernandez-Clotet A, Mesonero F, et al. Long-term outcomes of biological therapy in crohn\u2019s disease complicated with internal fistulizing disease: BIOSCOPE study from GETECCU. Am J Gastroenterol. 2023;118(6):1036\u201346.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"2963_CR29","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3393\/ac.2021.02.08","volume":"37","author":"JL Lee","year":"2021","unstructured":"Lee JL, Yoon YS, Yu CS. Treatment strategy for perianal fistulas in crohn disease patients: the surgeon\u2019s point of view. Ann Coloproctol. 2021;37(1):5\u201315.","journal-title":"Ann Coloproctol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02963-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02963-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02963-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:25:47Z","timestamp":1726244747000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02963-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,20]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2963"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02963-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,20]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sumesh Kachroo, Sabree Burbage and Caroline Kerner are employees of Janssen Scientific Affairs, LLC, a Johnson & Johnson company, and own stock\/stock options. Maryia Zhdanava, Porpong Boonmak, Aditi Shah, Patrick Lefebvre and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Janssen Scientific Affairs, LLC, a Johnson & Johnson company, which funded the development and conduct of this study and manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data were de-identified and comply with the patient requirements of the Health Insurance Portability and Accountability Act (HIPAA) of 1996; therefore, no review by an institutional review board was required per Title 45 of CFR, Part 46.101(b)(4) ().","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}